Numis Securities Ltd reiterated their buy rating on shares of Ergomed PLC (LON:ERGO) in a research report report published on Tuesday morning. Numis Securities Ltd currently has a GBX 267 ($3.31) target price on the stock.

A number of other brokerages have also recently commented on ERGO. Stifel Nicolaus reaffirmed a buy rating and issued a GBX 271 ($3.36) target price on shares of Ergomed PLC in a report on Tuesday, November 1st. N+1 Singer upped their target price on shares of Ergomed PLC from GBX 265 ($3.29) to GBX 275 ($3.41) and gave the company a buy rating in a report on Monday, November 7th.

Shares of Ergomed PLC (LON:ERGO) opened at 144.50 on Tuesday. Ergomed PLC has a 52-week low of GBX 117.00 and a 52-week high of GBX 172.00. The firm’s market capitalization is GBX 44.96 million. The stock’s 50 day moving average price is GBX 125.69 and its 200-day moving average price is GBX 125.62.

TRADEMARK VIOLATION NOTICE: “Ergomed PLC (ERGO) Receives “Buy” Rating from Numis Securities Ltd” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this article can be read at

Ergomed PLC Company Profile

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Stock Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related stocks with our FREE daily email newsletter.